Zeria Pharmaceutical’s fiscal year ending March 2026 recorded sales of \u00a589.1 billion (YoY +2.1%), net profit of \u00a58.4 billion (down 14.9% YoY), with an increased overseas sales ratio of 59.3%. The company expects revenue and profit growth this term, with dividends also planned to be increased.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4559","jir_company_name":"Zeria Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4559-20260508-01.pdf","jir_short_summary":"Zeria Pharmaceutical's fiscal year ending March 2026 recorded sales of \u00a589.1 billion (YoY +2.1%), net profit of \u00a58.4 billion (down 14.9% YoY), with an increased overseas sales ratio of 59.3%. The company expects revenue and profit growth this term, with dividends also planned to be increased.","jir_summary":"### Performance Overview\nThe consolidated financial results for the fiscal year ending March 2026 show sales of \u00a589.1 billion (YoY +2.1%), operating income of \u00a512.4 billion (+1.4%), and net profit of \u00a58.4 billion (\u221214.9%). The overseas sales ratio expanded to 59.3%, demonstrating solid growth in both the medical pharmaceuticals and consumer health care businesses. The medical pharmaceuticals segment performed well with ulcerative colitis and infectious disease treatments, while the consumer segment continued strong with the Heparize series. R&D expenses decreased to \u00a53.7 billion.\n\n### Outlook and Shareholder Impact\nFor the fiscal year ending March 2027, projections indicate sales of \u00a595.0 billion (+6.6%) and net profit of \u00a510.0 billion (+18.3%), aiming for revenue and profit growth. The dividend is planned to increase by \u00a52 to \u00a549 per share, reflecting a focus on shareholder returns. The company will promote overseas expansion and new drug development to achieve long-term growth.","jir_financial_highlights":"Sales: \u00a589,159 million (YoY +2.1%)\nNet profit attributable to owners of parent: \u00a58,454 million (YoY -14.9%)\nOperating income: \u00a512,374 million (YoY +1.4%)","jir_category":"","jir_hashtags":"#ZeriaPharmaceutical, #IRFinancialResults, #JapanStocks","jir_key_figures":"Sales: \u00a589,159 million (YoY +2.1%)\nNet profit attributable to owners of parent: \u00a58,454 million (\u221214.9%)\nDividend: \u00a549 (planned increase)","jir_meta_title":"\u3010Zeria Pharmaceutical\u3011Financial Results for 2026 | Sales of \u00a589.1 billion, Net Profit of \u00a58.4 billion increase","jir_meta_description":"Zeria Pharmaceutical's fiscal year ending March 2026 reported sales of \u00a589.1 billion and net profit of \u00a58.4 billion, with growth in overseas sales ratio and future outlook explained.","jir_og_title":"\u3010Zeria Pharmaceutical\u3011Financial Results for 2026 | Sales of \u00a589.1 billion, Net Profit of \u00a58.4 billion increase","jir_og_description":"Zeria Pharmaceutical's fiscal year ending March 2026 achieved sales of \u00a589.1 billion and net profit of \u00a58.4 billion, with positive growth and upcoming dividends and outlooks introduced.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9548,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-46204","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n